We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

107 hedge funds and large institutions have $53.9M invested in Infinity Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

983% more call options, than puts

Call options by funds: $390K | Put options by funds: $36K

9% less funds holding

Funds holding: 117107 (-10)

14% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 36

29% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 31

78% less capital invested

Capital invested by funds: $241M → $53.9M (-$187M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
107
Holders Change
-10
Holders Change %
-8.55%
% of All Funds
2.85%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
22
Increased
31
Reduced
36
Closed
31
Calls
$390K
Puts
$36K
Net Calls
+$354K
Net Calls Change
-$175K
Name Holding Trade Value Shares
Change
Change in
Stake
AIG
76
American International Group
New York
$37.6K -$2.07K -443 -2%
Invesco
77
Invesco
Georgia
$36K +$10.4K +2,219 +9%
BG
78
BlackRock Group
United Kingdom
$35K -$2.1K -448 -2%
VOYA Investment Management
79
VOYA Investment Management
Georgia
$33K
TRCT
80
Tower Research Capital (TRC)
New York
$31K +$101K +21,659 +1,444%
UBS AM
81
UBS AM
Illinois
$30K
SM
82
Sabby Management
Florida
$30K +$105K +22,500 New
Bank of America
83
Bank of America
North Carolina
$28K +$75.2K +16,072 +317%
PCM
84
Prelude Capital Management
New York
$24K +$74.9K +16,007 +698%
Wolverine Trading
85
Wolverine Trading
Illinois
$21K +$71.3K +15,257 New
Barclays
86
Barclays
United Kingdom
$20K +$68.7K +14,682 +4,862%
Public Employees Retirement Association of Colorado
87
Public Employees Retirement Association of Colorado
Colorado
$19K
Jacobs Levy Equity Management
88
Jacobs Levy Equity Management
New Jersey
$16K
Legal & General Group
89
Legal & General Group
United Kingdom
$10K
BJ
90
BlackRock Japan
Japan
$10K +$33.6K +7,184 New
Citigroup
91
Citigroup
New York
$9K -$138K -29,532 -82%
UBS Group
92
UBS Group
Switzerland
$9K +$22.3K +4,769 +207%
Teacher Retirement System of Texas
93
Teacher Retirement System of Texas
Texas
$8K +$435 +93 +2%
Canada Life
94
Canada Life
Manitoba, Canada
$3K
BNP Paribas Financial Markets
95
BNP Paribas Financial Markets
France
$2.27K +$8K +1,710 New
Manulife (Manufacturers Life Insurance)
96
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K -$151K -32,202 -95%
LTFS
97
Ladenburg Thalmann Financial Services
Florida
$2K -$505 -108 -7%
MFW
98
Mosaic Family Wealth
Missouri
$2K
Zurich Cantonal Bank
99
Zurich Cantonal Bank
Switzerland
$2K
Royal Bank of Canada
100
Royal Bank of Canada
Ontario, Canada
$2K +$7.56K +1,616 New

INFI Hedge Fund Activity: Q2 2016 in Review

107 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2016, worth a combined $53.9M — down 78% from $241M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of INFI and 22 opened new positions — a net loss of 9 holders — while 36 trimmed existing stakes and 31 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $24.2M. The largest seller was BB Biotech, exiting entirely with an estimated $14.2M sold.

  • 107 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2016, down from 117 in Q1 2016.
  • Funds reported $53.9M of Infinity Pharmaceuticals, Inc. stock for Q2 2016, down 78% quarter-over-quarter.
  • 22 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2016 and 31 closed out, a net change of -9 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2016 was BVF Inc, an estimated $24.2M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q2 2016 was BB Biotech, an estimated $14.2M sold.

Based on aggregated 13F filings for Q2 2016.